You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of novel Amadorins for Diabetic Peripheral Neuropathy
SBC: Praetego Inc Topic: 200PROJECT SUMMARY Diabetic peripheral neuropathy (DPN) is the most common diabetic complication. DPN is a leading cause for disability due to foot ulceration and amputation, gait disturbance, and fall-related injury. There is no FDA- approved disease modifying treatment for DPN, a condition affecting up to 50% of the estimated 30 million diabetic patients in the US. Neuropathy occurs in patients wit ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Multi-Modality Image Data Fusion and Machine Learning Approaches for Personalized Diagnostics and Prognostics of MCI due to AD
SBC: MS Technologies Corporation Topic: RAlzheimer’s Disease (AD) is a devastating neurodegenerative disease. The greatest treatment potential lies in early stages before irreversible brain damage occurs. Early treatment requires early detection of the disease. Imaging holds great promise for capturing early signs of AD. This capability can be substantially strengthened by integrating neuroimages of different modalities that characteri ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Development and testing of a behavioral activation mobile therapy for elevated depressivesymptoms
SBC: MOUNTAINPASS TECHNOLOGY LLC Topic: 104PROJECT SUMMARY/ABSTRACT Depression is the leading cause of disability worldwide, with more than 300 million people affected. Most adults with depressive symptoms make at least one annual visit to a primary care physician (PCP). As such, primary care offers a ripe opportunity to identify and treat adults with depressive symptomatology. Yet, depression has historically been undertreated in primary ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension
SBC: VASCULAR BIOSCIENCES, INC. Topic: NHLBIPUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of Pirenzepine for CIPN
SBC: WinSanTor, Inc. Topic: NCIPROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
InheRET: A SaaS solution to identify patients at increased risk for hereditary disease.
SBC: Inheret, Inc Topic: 102PROJECT SUMMARY This project is to expand the InheRET Inherited Risk Evaluation Tool to include recommendations for testing of patients at increased risk for hereditary disease, adding patient navigation features and customizable database entries for healthcare providers. This will include the development, integration and testing of InheRET 3.0 followed by pilot testing in 5 diverse clinics. InheR ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523
SBC: SignalRx Pharmaceuticals Inc. Topic: 102There is an unmet need to inhibit the key cancer promoting transcription factor MYCboth c MYC and MYCNthat act downstream of many cell receptors and signal transcription pathways to activate genes for cancer cell resistance and tumor growthTo datesmall molecule inhibitors of MYC have remained elusiveIn our Phase I STTRCAwe developed a lead compoundSFwhich displays potent orthogonal inhibitory acti ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDPROJECT SUMMARY The family of Filoviridae consisting of five ebolaviruses and two marburgviruses are causative agents of severe hemorrhagic fever with human case fatality rates ofTheepidemic of Ebola virus disease in West Africa was unprecedented both in geographic scope and size and highlighted the extent of the threat filoviruses could pose to global public health and the urgent need for develop ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Urine Diagnostics for Aspergillosis
SBC: PEARL DIAGNOSTICS, INC. Topic: NIAIDInvasive aspergillosisIAcontinues to cause morbidity and death in medically immune compromised patientslargely because we lack sensitive diagnostic tests that are easy to use during high risk periodsWe discovered that fungal galactofuranose containing antigens are excreted in urine of infected animals and peopleusing a novel monoclonal antibodymAbIn a phase I STTRwe engineered a lateral flow devic ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Testing a male oral contraceptive targeting Eppin
SBC: EPPIN PHARMA INC Topic: NICHDThe global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characte ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health